ClinicalTrials.gg
Not yet recruitingNCT07901413Updated Oct 28, 2026

Evaluation of ICP-B381 in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of ICP-B381 in Advanced Solid Tumor, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 1/2, Interventional, and Treatment

Updated Oct 28, 2026Newly registeredGo to Updates ↓
Phase
Phase 1/2
Study type
Interventional
Enrollment
348
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

To evaluate the safety, tolerability, efficacy and pharmacokinetic characteristics of ICP-B381 in the trial participants of advanced solid tumors

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Beijing InnoCare Pharma Tech Co., Ltd. is the lead sponsor of 61 studies on the registry; 38 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be at least 18 years old.
  2. Participants thoroughly understand study procedures, and voluntarily sign the written ICF
  3. (ECOG) performance status score 0-1.
  4. Expected survival time ≥3 months.
  5. Histopathologically confirmed castration-resistant prostate cancer (mCRPC) \& Other advanced solid tumor
  6. Agree to provide FFPE slides from archived tumor tissues collected within the past 2 years or fresh tumor (for archived samples, more recently collected specimens are preferred
  7. The organ function level must meet the prescribed standards
  8. All toxicities derived from previous anti-neoplasm treatments must have been resolved to Grade ≤1 (per V6.0)
  9. Effective measures should be taken from the date of signing the form until at least 6 months after the use of the last dose of the study drug
  10. Female participant of must have a negative blood pregnancy test at the screening visit
  11. Female participants must not breastfeed or plan pregnancy during the study and for at least 6 months after the last dose.
  12. Participants can communicate well with the Investigator and can complete the study according to the study protocol

Exclusion criteria

Exclusion Criteria:

  1. Other active malignant tumors occurred within 3 years before the first administration of the study drug
  2. Has previously received or is currently receiving the same type of drug or related treatment as stipulated in the protocol
  3. Has a previous medical history and adverse life history as specified in the protocol, or has a disease as specified in the protocol
  4. Has received cytotoxic chemotherapy, radical radiotherapy, molecular targeted therapy, immunotherapy, anti-tumor vaccine therapy, cytokine therapy, or other anti-cancer drugs with an elution time not meeting the protocol requirements
  5. Had active bleeding within 2 months before screening or had or significant bleeding tendency, or was experiencing bleeding symptoms due to taking anticoagulant drugs or other medical interventions
  6. Had major surgery within 28 days before the first administration or minor surgery within 2 weeks before the first administration
  7. Has received systemic drugs as stipulated in the protocol for 14 days before the first administration
  8. Has a history of severe allergic reactions to the active ingredient, non-active ingredients in the drug, or antibody-based drugs
  9. Had the first administration within 2 weeks before or is planned to use drugs or foods with strong inhibitory or inducing effects on cytochrome P450 before the study
  10. Has any mental or cognitive disorders that may limit their understanding, execution of the form, and compliance with the study
  11. Situations that the investigator deems unsuitable for participating in this study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
348 participants (estimated)

Study arms

  • Experimental
    ICP-B381

    Drug: ICP-B381

Interventions

  • DrugICP-B381

    ICP-B381 will be administered by intravenous infusion every 3 weeks (Q3W) until disease progression (PD) or the occurrence of unacceptable toxicity or withdrawal from the study for other reasons (whichever occurs first).

06

What researchers measure

Primary outcomes

  1. The type, severity (assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0 [NCI-CTCAE V6.0]), relationship to the investigational product, and incidence rate of adverse event (AE) and serious advers

    Time frame: 2 years

  2. The type, severity (assessed according to NCI-CTCAE V6.0), and incidence rate of dose limiting toxicity (DLT)

    Time frame: 2 years

  3. Single-agent Recommended Dose (RD) and/or Maximum Tolerated Dose (MTD)

    Time frame: 2 years

  4. Participants with prostate cancer: Prostate-specific antigen (PSA50) response rate evaluated by Investigator according to Prostate Cancer Working Group 3 (PCWG3) criteria

    Time frame: 2 years

  5. Participants with other tumor types: Investigator-assessed Objective response rate (ORR) according to Response Evaluation Criteria In Solid Tumors (RECIST) V1.1 criteria

    Time frame: 2 years

  6. The optimal dosing regimen for the subsequent study of ICP-B381

    Time frame: 2 years

Secondary outcomes

  1. Maximum Concentration (Cmax)

    Time frame: 2 years

  2. Time to Maximum Plasma Concentration (Tmax)

    Time frame: 2 years

  3. Half-life (T1/2)

    Time frame: 2 years

  4. Area Under the Serum or Plasma Concentration-Time Curve (AUC0-∞ and AUC0-t)

    Time frame: 2 years

  5. Apparent Clearance Rate (CL/F)

    Time frame: 2 years

  6. Terminal Apparent Volume of Distribution (Vz/F)

    Time frame: 2 years

  7. Steady-state Pharmacokinetic Parameters

    Time frame: 2 years

  8. ORR

    Time frame: 2 years

  9. Disease Control Rate (DCR)

    Time frame: 2 years

  10. Duration of Response (DOR)

    Time frame: 2 years

  11. Participants with prostate cancer: radiographic progression-free survival (rPFS) evaluated by the Investigator according to RECIST V1.1 criteria (for soft tissue lesions) and PCWG3 criteria (for bone lesions)

    Time frame: 2 years

  12. Participants with prostate cancer: changes in serum PSA levels compared to baseline during the study: PSA50 response rate

    Time frame: 2 years

  13. Participants with prostate cancer: PSA90 response rate

    Time frame: 2 years

  14. Participants with prostate cancer:12-week PSA response rate

    Time frame: 2 years

  15. Participants with prostate cancer: time to PSA progression (TTPP)

    Time frame: 2 years

  16. Time to First Subsequent Therapy (TFST)

    Time frame: 2 years

  17. Overall Survival (OS)

    Time frame: 2 years

  18. Participants with prostate cancer: incidence rate of symptomatic skeletal event (SSE)

    Time frame: 2 years

  19. Participants with prostate cancer: time to first symptomatic skeletal event (TTSSE)

    Time frame: 2 years

  20. Incidence rate of anti-drug antibody (ADA) against ICP-B381

    Time frame: 2 years

  21. Types, severity (assessed according to NCI-CTCAE V6.0), relationship with the investigational product, and incidence rate of AE and SAE

    Time frame: 2 years

07

Study locations

1 site
08

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07901413
Responsible party
Sponsor
First posted
Oct 28, 2026
Start date
Nov 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
Oct 28, 2026

Study contacts

Jingnan Yang
Contact
CO-Clinicaltrial@innocarepharma.com
010-66609990

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion